Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Capital Expenditures (2023 - 2025)

bioAffinity Technologies (BIAF) has disclosed Capital Expenditures for 3 consecutive years, with -$3646.0 as the latest value for Q3 2025.

  • On a quarterly basis, Capital Expenditures fell 138.75% to -$3646.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $60568.0, a 7.73% decrease, with the full-year FY2024 number at $79083.0, up 245.31% from a year prior.
  • Capital Expenditures was -$3646.0 for Q3 2025 at bioAffinity Technologies, down from $13427.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $50786.0 in Q1 2025 to a low of -$13442.0 in Q4 2023.
  • A 3-year average of $14777.5 and a median of $9410.0 in 2024 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: surged 5468.05% in 2024, then plummeted 138.75% in 2025.
  • bioAffinity Technologies' Capital Expenditures stood at -$13442.0 in 2023, then surged by 100.01% to $1.0 in 2024, then crashed by 364700.0% to -$3646.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Capital Expenditures are -$3646.0 (Q3 2025), $13427.0 (Q2 2025), and $50786.0 (Q1 2025).